logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Amgen's Oncology Product AMG-510 Meeting An Unmet Need for Kras G12C Mutated Cancers

Amgen's Outperforming After being boxed in, for the past couple of weeks, Amgen’s ( AMGN ) stock finally outperformed. The firm was outperforming silently with regard to its financial results, sciences, technologies, pipeline products and multiple newly approved products drugs.  ...

Read More

September 9, 2019

0

About RegenxBio's Agreement with Clearside Biomedical and More

Diseases of the Back of the Eye Diseases of the back of the eye, such as: age-related wet macular degeneration, diabetic retinopathy and diabetic macular edema, are currently managed with injections of anti-vascular endothelial growth factor ( anti-VEGF ) drugs...

Read More

September 10, 2019

0

Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide ( CGRP ) monoclonal antibody drugs have been approved in 2018 and 2019. They are: Aimovig for Amgen...

Read More

September 16, 2019

0

Compugen Has Encouraging News

Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701 Compugen ( CGEN ) announced that the first patient has been dosed in the Phase 1/2 study of the triple combination of COM701 - Compugen’s first-in-class anti-PVRIG antibody, with...

Read More

September 8, 2020

0

Compugen: More Highlighted News

Compugen Exclusive License Agreement with AstraZeneca In April 2018 Compugen ( CGEN ) and AstraZeneca ( AZN ) entered into an agreement by which Compugen provided an exclusive license to AstraZeneca for the development of bispecific and multi-specific antibody products...

Read More

December 23, 2020

0

Atara Allogeneic Product ATA188 Will Confirm Whether EBV Infecting B Cells Could Cause a Difficult to Treat Kind of MS

Atara Biotherapeutics ATA188 for MS Atara Biotherapeutics ( ATRA ) announced the presentation of initial efficacy data as well as updated safety results from its ongoing Phase 1 study of the firm’s product ATA188 for the treatment of a progressive...

Read More

September 17, 2019

0

At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

bluebird bio Has Promising Results from Its Lenti-D Gene Therapy for CALD Good results have come from  bluebird bio’s ( BLUE ) updated results in the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy...

Read More

September 20, 2019

0

Cassava Sciences Promising and Encouraging Results of Its Alzheimer's Disease Product Sumifilam

Cassava Sciences Study Results of Sumifilam for Alzheimer's Disease Prohost is happy to inform our subscribers that our positive opinion about Cassava Sciences' product created and developed for Alzheimer’s disease happens to be right. Cassava Sciences ( SAVA ) announced today...

Read More

September 14, 2020

0

Inovio: Exciting News Published in The Lancet

Inovio Phase 1 Data of INO-4800 for COVID-19 Peer-reviewed Phase 1 data shows Inovio COVID-19 DNA Vaccine Candidate, INO-4800, to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses. INO-4800 demonstrates favorable safety and tolerability. No...

Read More

December 24, 2020

0

Seattle Genetics: Two New Oncology Collaborations with Merck

Seattle Genetics Two New Strategic Oncology Collaborations with Merck Seattle Genetics ( SGEN ) and Merck ( MRK ) , known as MSD outside the United States and Canada, announced today two new strategic oncology collaborations. The companies will globally...

Read More

September 14, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 102
  • 103
  • 104
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy